The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2008

Filed:

Dec. 18, 2000
Applicants:

Mathieu Hubertus Maria Noteborn, Leiderdorp, NL;

Guus Koch, Lelystad, NL;

Inventors:

Mathieu Hubertus Maria Noteborn, Leiderdorp, NL;

Guus Koch, Lelystad, NL;

Assignee:

Leadd B.V., Leiden, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); C07K 14/01 (2006.01); C07K 16/46 (2006.01); C07K 19/00 (2006.01); C12N 15/62 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/34 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
Abstract

The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Expression in the same cell of at least VP1 plus VP2 is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.


Find Patent Forward Citations

Loading…